Journal
DRUG DISCOVERY TODAY
Volume 20, Issue 11, Pages 1372-1381Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2015.09.001
Keywords
-
Categories
Funding
- Bill & Melinda Gates Foundation
- Muscular Dystrophy Association
- ALS Therapy Alliance
Ask authors/readers for more resources
Hypoxic-ischemic (H-I) brain injury in newborns is a major cause of morbidity and mortality that claims thousands of lives each year. In this review, we summarize the promising neuroprotective agents tested on animal models and pilot clinical studies of neonatal H-I brain injury according to the different phases of the disease. These agents target various phases of injury including the early phase of excitotoxicity, oxidative stress and apoptosis as well as late-phase inflammatory reaction and neural repair. We analyze the cell survival and cell death pathways modified by these agents in neonatal H-I brain injury. We aim to 'build a bridge' between animal trials of neuroprotective agents and potential candidate treatments for future clinical applications against H-I encephalopathy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available